
Wrong treatment of sore throats is fuelling antimicrobial resistance
This issue is particularly evident in the treatment of sore throats, which are usually the result of viral infections and do not require antibiotics.
Despite this, overprescription remains alarmingly high, especially in primary care settings.
Over the past decade, Malaysia has witnessed persistent and concerning patterns in the misuse of antibiotics for sore throats.
A 2022 study in public primary care clinics found that only 2.8% of sore throat cases were caused by group A Streptococcus – the only common bacterial cause warranting antibiotics.
Yet, antibiotics were prescribed to 22.3% of patients, with over 90% of those prescriptions being unnecessary.
In private clinics, the situation is even more pronounced: only 42.9% of prescriptions for sore throats were appropriate, while 58.5% were excessive.
On the rise again
The Health Ministry has consistently raised alarms about the escalating issue of antimicrobial resistance (AMR), yet the trend of overprescribing antibiotics remains prevalent due to several key factors: Patient misconceptions A 2021 study in the journal Patient Preference and Adherence showed that 79.1% of Malaysians mistakenly believe antibiotics can cure viral infections, and 77% mistakenly believe they can cure coughs and colds.
Doctor practices
Many physicians in both public and private primary care settings are often influenced by patient expectations and diagnostic uncertainty, leading to the prescription of antibiotics even when they are not clinically indicated.
Although antibiotic use temporarily declined during the Covid-19 pandemic due to heightened public health awareness, usage rates have since rebounded, particularly in the private sector.
In 2021, antibiotic utilisation in private primary care was nearly ten times higher than in public clinics.
The misuse of antibiotics contributes directly to the rise of antibiotic-resistant superbugs, which pose a significant threat to public health.
A 2021 study from a Malaysian tertiary hospital, published in the journal Pathogens , identified high rates of beta-lactam resistance among common respiratory pathogens such as Streptococcus pneumoniae and Haemophilus influenzae .
These pathogens, once easily treatable, now present serious challenges to effective treatment due to resistance.
Community-acquired infections with methicillin-resistant Staphylococcus aureus (MRSA) are also becoming more common.
ALSO READ: New antibiotics desperately needed as germs become more resistant
A clinical consensus
Group A Streptococcus bacteria (orange), seen here in a colourised scanning electron microscope image, are the only common cause of sore throats that warrant the use of antibiotics. — NIAID
The World Health Organization's Global Antimicrobial Resistance and Use Surveillance System (GLASS) has categorised Malaysia as a high-alert nation due to the increasing threat of AMR.
In comparison to other Asian countries, Malaysia is among the leading nations in terms of antibiotic overuse.
To address this, the 2024 Malaysian Sore Throat Consensus – formulated and finalised in 2023 – is set to be officially launched on July 22 (2025).
Developed through collaboration by a multidisciplinary panel of Malaysian experts, the consensus reflects updated evidence and local context, offering a unified, evidence-based approach to managing sore throats.
Contributors included representatives from primary care, otorhinolaryngology (ear, nose and throat, or ENT), paediatrics, microbiology and infectious diseases, respiratory medicine, pharmacy, and general practice, spanning both public and private sectors.
The consensus outlines several key clinical criteria and tools to guide appropriate diagnosis and management, including:
Antibiotics should not be the first-line treatment unless group A Streptococcus infection is confirmed.
Overprescription drives AMR. > Use of the McIsaac Score (Modified Centor Score)
This is a validated scoring system assessing bacterial likelihood based on symptoms such as fever, lymph node swelling and absence of cough.
A score of two or less suggests viral infection, while a score of three or less increases the likelihood of group A Streptococcus infection.
Rapid antigen detection tests for group A Streptococcus improve diagnostic certainty and reduce unnecessary antibiotic prescriptions.
Non-steroidal anti-inflammatory drugs (NSAIDs) like flurbiprofen lozenges or sprays, are recommended for pain relief, addressing patient needs without resorting to antibiotics. > Multidisciplinary approach
Developed by a panel with broad clinical representation, the consensus ensures relevance and applicability across Malaysia's diverse healthcare settings.
A stubborn problem
Despite ongoing awareness efforts, misconceptions and behavioural gaps remain entrenched.
Many patients continue to pressure clinicians into prescribing antibiotics and incomplete courses of antibiotics are still common.
National surveys confirm that public understanding remains low, highlighting the urgent need for continuous education campaigns and for healthcare professionals to serve as active educators.
AMR also brings severe economic and environmental consequences.
By 2050, the World Bank estimates that AMR could shrink the global economy by up to 3.8% and push 28 million people into poverty.
Treating resistant infections is up to three times more expensive than treating non-resistant ones.
Overprescribed antibiotics frequently end up in wastewater, contaminating soil and rivers, and accelerating the spread of resistance in the environment.
ALSO READ: Study: Superbugs expected to kill 39 million by 2050
Malaysia has already made significant strides, such as implementing stewardship programmes and launching public campaigns, but urgent, bolder steps are needed.
One practical and meaningful move within the next one to three years would be to strengthen antibiotic stewardship policies in primary care, particularly for upper respiratory tract infections.
This could include making clinical scoring tools or rapid antigen tests mandatory before antibiotics are prescribed and encouraging voluntary benchmarking of prescribing rates in clinics.
This approach promotes accountability without public shaming, while supporting clinicians in prescribing more wisely.
Looking ahead, the launch of the Malaysian Sore Throat Consensus represents a timely and critical step forward.
Grounded in local data and international best practices, this national initiative, supported by British multinational health and hygiene consumer goods company Reckitt, aims to empower frontline providers with the tools, clarity and confidence to combat antibiotic misuse effectively.
With firm, but supportive policies, cross-sector collaboration and consistent public education, Malaysia has the potential not only to safeguard public health domestically, but to also lead Asean in combating AMR on a regional scale.
Professor Dr Baharudin Abdullah is a senior consultant otorhinolaryngologist and head and neck surgeon at Universiti Sains Malaysia. For more information, email starhealth@thestar.com.my. The information provided is for educational and communication purposes only, and should not be considered as medical advice. The Star does not give any warranty on accuracy, completeness, functionality, usefulness or other assurances as to the content appearing in this article. The Star disclaims all responsibility for any losses, damage to property or personal injury suffered directly or indirectly from reliance on such information.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Sun
4 hours ago
- The Sun
Cabinet addresses ATS drug abuse among youth in Malaysia
KOTA BHARU: The growing issue of Amphetamine Type Stimulants (ATS) addiction among young Malaysians has reached the Cabinet level, according to Youth and Sports Minister Hannah Yeoh. She revealed that the government is working with the Malaysian Communications and Multimedia Commission (MCMC) to tackle online drug sales, which are increasingly targeting minors. 'The current trend shows primary school pupils are getting involved with ATS. Some access it through online platforms like WhatsApp,' Yeoh told Bernama after visiting the Kota Bharu Narcotics Addiction Rehabilitation Centre (PUSPEN). She urged parents to monitor their children's smartphone use closely, stressing the need for supervision. Yeoh emphasised the ministry's commitment to helping young drug users seek voluntary treatment at PUSPEN. Parents noticing behavioural changes in their children were advised to contact the centre immediately. National Anti-Drug Agency (AADK) data for 2024 revealed 117,000 individuals aged 15 to 39 were involved in drug abuse, with Kelantan recording the highest addiction rates. Yeoh shared insights from her discussions with PUSPEN clients, some as young as 17, who began using drugs in primary school. 'While the trend is alarming, PUSPEN's 79% rehabilitation success rate is encouraging. The real challenge is preventing relapses by keeping recovered individuals away from old networks,' she said. Yeoh also met parents, urging early intervention and openness to seeking help. The ministry collaborates with AADK on awareness campaigns, including video screenings in cinemas like TGV. 'Young people must know they're not alone—support is available,' she added.


The Sun
4 hours ago
- The Sun
M'sia sets medical milestone with conjoined twin separation in 13-hour surgery
PETALING JAYA: Malaysian surgeons have achieved another milestone in paediatric medicine by successfully separating three-month-old conjoined twins at Hospital Tunku Azizah (HTA), a government hospital in Kuala Lumpur that specialises in paediatrics and obstetrics & gynaecology. According to a statement posted on HTA's official Facebook page, the male twins were born with a rare condition known as Omphalo-Ischiopagus Tetrapus Conjoined Twin, in which the babies were joined at the abdomen and pelvis, sharing four legs. The complex and delicate procedure was led by four senior doctors—Dr Mohd Yusof Abdullah, Datuk Dr Zakaria Zahari, Dr Intan Zarina Fakir Mohamed, and Dr Phang Yee Yun. They were supported by a dedicated team of experienced paediatric surgeons from HTA and Hospital Kuala Lumpur (HKL). The 13-hour surgery began at 8:30am on June 24, with the successful separation completed at 5:43pm. The full operation concluded at 9:48pm. 'Alhamdulillah, the surgery went smoothly and both babies are now stable and receiving treatment in the Paediatric Intensive Care Unit (PICU),' the hospital reported. This remarkable operation marks the fourth successful separation of conjoined twins at HTA since 2019, and the 19th such case in the combined history of HTA-HKL surgical collaborations.


The Sun
10 hours ago
- The Sun
Top TV Anchors Lead National Stem Cell Awareness Drive
FOUR of Malaysia's most beloved TV news anchors — Gan Jiang Han, Lim She Ting, Tan Ley Teng, and Marsila Hassan — have stepped forward as the first YAKIN AMBASSADORS in a groundbreaking national initiative to demystify and democratise regenerative medicine. Launched by Yakin Splendour Global Holdings Bhd, the strategic brand arm of Yakin Medic Sdn Bhd, the campaign titled 'YAKIN Stem Cell Technology • Now Within Your Reach' is set to reshape how Malaysians understand and access stem cell therapy. At its heart, YAKIN AMBASSADORS is about building trust, sparking meaningful conversations, and showing that regenerative therapy is not only real — it's reachable. 'The vision behind YAKIN AMBASSADORS is to bridge the gap between science and society. 'This initiative is not just about public engagement — it's about sparking meaningful conversations, reducing misconceptions, and inspiring individuals to take control of their health through innovative and proven medical solutions,' said Patrick Tan, founder and chief executive officer of Yakin Group of Companies. Witnessed by Deputy Minister of Science, Technology and Innovation Datuk Mohammad Yusof Apdal, the signing ceremony signaled a pivotal moment for Malaysian healthcare, merging innovation with relatable advocacy. 'This initiative not only offers renewed hope to patients battling chronic and degenerative illnesses but also elevates Malaysia's standing in the field of medical tourism. 'I am proud to see local companies like Yakin Splendour actively transforming the nation's healthcare landscape, in line with the aspirations of the 12th Malaysia Plan and the national science, technology, and innovation agenda,,' said Yusof. A Personal and National Mission Founded in 2014, Yakin Medic has grown from a clinical data unit into one of Malaysia's foremost regenerative and stem cell therapy providers. Today, it offers hope to patients suffering from chronic diseases, age-related conditions, and degenerative illnesses. For Tan, the mission is deeply personal. After surviving third-degree burns in an accident, the very therapies he once advocated became vital to his recovery. 'I believed in the science, but I never imagined I'd become a patient myself. 'That experience changed everything. It became personal. 'Through further research, we found stem cells offered powerful solutions to these widespread health issues. It's one thing to believe in the science. It's another to be saved by it,' Tan explained. In September 2024, Yakin Medic entered into a technical collaboration with China-based IASO Biotherapeutics, combining CAR-T cell technology with regenerative therapies and iTeraCare resonant technology — a strategic move to position Malaysia as a regional biotech leader. Industry Partnerships and Expansion Adding momentum to the campaign, SceneFis Aesthetic, a prominent beauty centre and distributor for Yakin Splendour, has committed over RM400,000 in a strategic alliance. The partnership supports wellness, rejuvenation, and skin health — illustrating the vast potential of stem cell applications in both healthcare and aesthetics. 'We are proud to collaborate with Yakin Group. 'We believe these innovations can benefit many Malaysians seeking wellness and rejuvenation,' said Vesley Lee Siew Khim, Managing Director of SceneFis Aesthetic. A Vision for the Future Yakin Splendour is working to reduce the cost of stem cell therapy through bioreactor-based mass production, aiming to make treatments more affordable in the next two years. But safety and scientific integrity remain top priorities. 'This is a field that can't be rushed. Safety, science, and standards must always come first. 'Real science takes patience. Clinical trials, global standards, consistent quality and all of that matter because lives are at stake,' said Tan. Over the coming months, the YAKIN AMBASSADORS will participate in outreach programmes, community events, and storytelling initiatives that humanize stem cell therapy and offer real-world insight into its benefits. 'This is not just a campaign. It's a movement that uplifts, educates, and connects. 'It's about showing Malaysians that this isn't some distant or elitist science — it's something real, and it's here,' said Datuk Steven Lai, Director of Yakin Splendour Global Holdings Bhd.